The production of recombinant proteins is a cornerstone of modern biotechnology, with the methylotrophic yeast Pichia pastoris being a popular choice due to its high productivity and capacity for post-translational modifications. However, hypermannosylation, a common trait in yeast protein glycosylation, can limit the use of these proteins in biopharmaceutical applications. To address this issue, glyco-engineered yeast strains have been developed to produce more homogeneously glycosylated proteins. In a recent study, different glyco-engineered Pichia pastoris strains were compared in terms of growth, physiology, and recombinant protein production, shedding light on the intricate interplay between glycosylation patterns and cellular behavior.
The study focused on two main glyco-engineered strains: one producing Man5GlcNAc2 glycans and another producing Man8–10GlcNAc2 glycans, in comparison to a wild type strain. The research delved into the morphological traits of these strains during the production of a model protein, horseradish peroxidase C1A (HRP C1A), in shake-flask cultivations. Interestingly, both glyco-engineered strains exhibited larger single and budding cells and a propensity for cellular agglomeration, with the cores of these agglomerates showing decreased viability. Despite these challenges, the Man5GlcNAc2-producing strain displayed superior growth, physiology, and HRP C1A productivity compared to the Man8–10GlcNAc2-producing strain.
A key aspect of the study was the evaluation of these glyco-engineered strains in a bioreactor setting, providing a controlled environment for a more in-depth analysis. By conducting dynamic methanol pulsing experiments, the researchers uncovered optimal conditions for HRP C1A productivity in the Man5GlcNAc2-producing strain, particularly at a temperature of 30°C. This marked the first comprehensive assessment of growth, physiology, and recombinant protein production of a Man5GlcNAc2-producing strain in a bioreactor, offering valuable insights into the behavior of these engineered yeast strains under industrial-scale conditions.
One of the intriguing findings of the study was the impact of glycan length on cellular agglomeration and viability. The shorter glycan structures on the cell surface of glyco-engineered strains were linked to increased cellular agglomeration, potentially affecting metabolic activity and recombinant protein production. Despite these challenges, the production of Man5GlcNAc2-glycosylated HRP C1A was feasible, yielding active protein comparable to the wild type strain. However, it was noted that the thermal stability of HRP C1A was negatively affected by reduced glycosylation, highlighting the intricate relationship between glycosylation patterns and protein properties.
Further analysis in the bioreactor setting allowed for a detailed comparison of physiological parameters among different strains. The Man5GlcNAc2-producing strain exhibited similar growth rates to the wild type strain but showcased a more efficient conversion of substrate to biomass, potentially attributed to the altered glycosylation machinery. Notably, the glyco-engineered strains demonstrated superior productivity during MeOH induction, with the Man5GlcNAc2-producing strain outperforming the others in terms of HRP C1A productivity and specific uptake rates.
Moreover, the study delved into the enzymatic kinetics and thermal stability of the recombinantly produced HRP C1A from the glyco-engineered strain. While the enzyme’s affinity towards its substrate remained consistent across different glycosylation patterns, the thermal stability was notably diminished in the Man5GlcNAc2-glycosylated protein compared to the wild type variant. This emphasizes the crucial role of glycosylation in protein stability and underscores the need for a comprehensive understanding of glycan structures in protein engineering.
In conclusion, this research provides valuable insights into the intricate biology of recombinant peroxidase production in glyco-engineered yeast strains. By unraveling the complex interplay between glycosylation patterns, cellular morphology, and protein productivity, the study advances our understanding of biotechnological processes in yeast systems. The findings pave the way for further optimization of glyco-engineered strains for enhanced protein production and underscore the importance of glycan engineering in biopharmaceutical applications.
Takeaways:
– Glyco-engineered yeast strains offer a solution to hypermannosylation limitations in recombinant protein production.
– Cellular agglomeration and viability can be influenced by glycan length on the cell surface.
– Bioreactor studies provide a controlled environment for evaluating strain behavior at an industrial scale.
– Understanding glycosylation patterns is crucial for optimizing protein stability and production efficiency.
Tags: bioreactor, secretion, yeast, upstream
Read more on pmc.ncbi.nlm.nih.gov